The study looked at how changing regulations in Norway affected generic competition and drug prices. They found that when reference pricing was introduced in 2003, it led to lower prices for brand-name drugs, not generic ones. This change also increased competition among generic drugs, reducing the market share of brand-name drugs. Overall, the new regulation resulted in significant cost-savings for consumers.